
The tortoise, the hare and the hybrid: Regional effects of entrepreneurial apprenticeships

Mary Donegan, Maryann Feldman,
Allison Forbes, Nichola Lowe
University of North Carolina, Chapel Hill

Larger question: How are places transformed?






The Research Triangle Park



Bioscience in the Park




Entrepreneurial bioscience firms



Apprenticeships: The backbone of new firm formation

- Jacobs' (1972) "breakaway firms"
 - Medieval apprenticeship system
 - Locally-oriented
 - Tied to regional vibrancy




Apprenticeships: The backbone of new firm formation, cont.

- Scholarship largely divided into two strains:
- Corporate spawns
 - Business experience and professional networks
 - Silicon Valley Fair-Children
 - Old Motor Works
- Academic entrepreneurship & university spinouts
 - Translation of research findings

Contextualizing apprenticeships


Diverse academic and corporate apprenticeship models, within the same region and within the same industry



Data Used in Analysis

- Feldman-Lowe Circling the Triangle database
 - 425 *de novo* entrepreneurial life sciences firms (1990 to 2012)
 - Continually updated
 - Draws from primary and secondary sources
- National Establishment Time Series database (NETS)
 - Birth and death years
 - Employment data

Feldman-Lowe database: Firm forensics



Founder team types: Prior experience in the region

- Academic apprenticeships:
 Duke, UNC, North Carolina State
- Prominent corporate apprenticeships:
 GSK, Pfizer, Ciba-Geigy, DuPont, Eli Lilly
- Other entrepreneurial firms

Founder team types: Prior experience in the region, cont.

- <u>Academic</u>: All founders have experience at region's universities, and only at these universities
- <u>Big pharma</u>: All founders have experience at region's prominent corporations, and only at these corporations
- <u>Second generation entrepreneurs (SGE)</u>: All founders have experience at entrepreneurial companies in the region, and only at these companies
- <u>Hybrid</u>: A founding team with combined <u>Academic</u>, <u>Big</u> <u>pharma</u>, and <u>SGE</u> experience, and only with these backgrounds
- Other: Founders don't fit in the previous categories


Firm attributes and outcomes

Key differences in firm attributes

 Birth year, subsector, founding team size, institutional supports


Relationships between founder team type and:

- Survival
- Labor market impact
- Funding



Entrepreneurial life science firms in the RTP, 1990-2012

Number of Companies by Type and Year of Establishment



Founding teams

| | | Mean number of | Founders per company | | | |
|------------|-----------------|-------------------|----------------------------------------|----------|----------|--|
| Firm type | Number of firms | | Number & percent of firm type subtotal | | | |
| | founders | | 1 | 2 | 3+ | |
| All | 425 | 1.87 | 198 (47) | 127 (30) | 100 (24) | |
| Academic | 56 | 1.48 | 38 (68) | 11 (20) | 7 (13) | |
| Big pharma | 33 | 1.36 | 23 (70) | 8 (24) | 2 (6) | |
| SGE | 33 | 1.15 | 29 (88) | 3 (9) | 1 (3) | |
| Hybrid | 104 | 2.10 | 39 (38) | 32 (30) | 28 (32) | |
| Other | 211 | 2.08 | 108 (36) | 105 (35) | 90 (43) | |

Life science subsectors


| | | Life science subsectors | | | | | |
|------------|----------------|---------------------------------------------------|--------------------|----------------------------------|---------------|--|--|
| F: 4 | Number offirms | Number of firms and percent of firm type subtotal | | | | | |
| Firm type | | Contract research (CRO) | Medical devices | Drug development & biotech | Other sectors | | |
| All | 425 | 72 (17) | 73 (17) | 213 (50) | 67 (16) | | |
| Academic | 56 | 9 (16) | 12 (21) | 29 (52) | 6 (11) | | |
| Big pharma | 33 | 9 (27) | 2 (6) | 19 (58) | 3 (9) | | |
| SGE | 33 | 8 (24) | 2 (6) | 10 (30) | 13 (39) | | |
| Hybrid | 104 | 19 (18) | 17 (16) | 59 (57) | 9 (9) | | |
| Other | 211 | 32 (15) | 40 (19) | 103 (49) | 36 (17) | | |

Institutional supports


| | Average | | Institutional Supports | | | | | |
|------------|-----------------|--------------------------|---------------------------------------|---------|---------|---------|--------|--|
| Firm type | Number of firms | number of supports | Number and percent of firm type total | | | | | |
| | | | 0 | 1 | 2 | 3-9 | 10+ | |
| All | 425 | 1.62 | 236 (56) | 74 (17) | 36 (9) | 66 (16) | 12 (3) | |
| Academic | 56 | 2.52 | 26 (46) | 8 (14) | 5 (9) | 14 (25) | 3 (5) | |
| Big pharma | 33 | 1.61 | 22 (67) | 4 (12) | 1 (3) | 5 (15) | 1 (3) | |
| SGE | 33 | 0.69 | 24 (72) | 5 (15) | 0 (0) | 3 (19) | 1 (3) | |
| Hybrid | 104 | 1.73 | 56 (54) | 14 (14) | 13 (13) | 19 (18) | 1 (1) | |
| Other | 211 | 1.48 | 114 (54) | 46 (22) | 20 (10) | 25 (12) | 6 (3) | |

Employment

Mean employment, by firm type and by year



Median employment, by firm type and by year



Survival


| | | Survival to Year 3 | | Survival to Year 5 | | Survival to Year 10 | |
|------------|-------|--------------------|----------------------------|--------------------|----------------------------|---------------------|----------------------------|
| Firm type | Firms | Potential | Actual, number and % | Potential | Actual, number and % | Potential | Actual, number and % |
| All | 425 | 375 | 357 (95) | 313 | 291 (93) | 172 | 139 (81) |
| Academic | 56 | 49 | 48 (98) | 40 | 39 (98) | 19 | 18 (95) |
| Big pharma | 33 | 30 | 28 (93) | 22 | 20 (91) | 16 | 16 (100) |
| SGE | 33 | 30 | 28 (93) | 26 | 24 (92) | 18 | 15 (83) |
| Hybrid | 104 | 87 | 85 (98) | 67 | 60 (90) | 33 | 23 (70) |
| Other | 211 | 189 | 178 (94) | 166 | 155 (93) | 92 | 70 (76) |

Funding

| Eium tung | Number of | Firms receiving funding, number & percent | | | |
|------------|-----------|-------------------------------------------|-----------------|--|--|
| Firm type | firms | Public funding | Private funding | | |
| All | 425 | 137 (32) | 127 (30) | | |
| Academic | 56 | 28 (50) | 11 (20) | | |
| Big pharma | 33 | 8 (24) | 8 (24) | | |
| SGE | 33 | 6 (18) | 5 (15) | | |
| Hybrid | 104 | 42 (40) | 40 (40) | | |
| Other | 211 | 58 (28) | 67 (32) | | |

Regional apprenticeships: The tortoise, the hare and the hybrid

- Success isn't consistently dominated by one apprenticeship type
- Big pharma firms—our hares—jump ahead in employment
 - Academics—our tortoises—catch up, as do hybrids
 - Others are very strong
- Academic and big pharma firms survive longer
- Funding is where hybrids shine
- SGE lags, but this is likely due to
 - High overlap with Other
 - Further distance from core bioscience activities



Firm founding years

| Firm type | Firms | | Firm establishment year | | |
|------------|--------|------------------|-------------------------|-------------|--|
| | Number | Percent of total | Median | Mean (sd) | |
| All | 425 | 100% | 2005 | 2004.3(5.2) | |
| Academic | 56 | 13% | 2005 | 2004.7(5.1) | |
| Big pharma | 33 | 8% | 2005 | 2003.2(6.1) | |
| Hybrid | 104 | 24% | 2006 | 2005.5(4.7) | |
| SGE | 33 | 8% | 2003 | 2003.2(5.3) | |
| Other | 211 | 50% | 2005 | 2003.8(5.2) | |

Events

| Firm type | Number of – | Merger or acquisition: | IPO: |
|------------|-------------|------------------------|------------|
| | firms: | Number and percent | Number and |
| | 1111113. | Number and percent | percent |
| All | 425 | 19 (5) | 8 (2) |
| Academic | 56 | 2 (4) | 1 (2) |
| Big pharma | 33 | 3 (9) | 3 (9) |
| SGE | 33 | 1 (3) | 1 (3) |
| Hybrid | 104 | 4 (4) | 1 (1) |
| Other | 211 | 10 (5) | 2 (1) |